Exo, a Silicon Valley firm recognized for its in-development handheld ultrasound system, introduced $40 million in new funding yesterday. GlaxoSmithKline’s Investor Motion Potential Enterprise Capital fund was among the many Collection B+ spherical’s unnamed buyers.
Exo stated in its announcement that will probably be utilizing the funds to wrap up product growth for that system, and to carry its information and workflow apps to market.
“Exo is making a platform expertise that may drive true adoption of level of care imaging in emergency rooms and significant care items, can facilitate superior surgical robotics and endoscopic procedures, and will allow therapeutic modalities in non-invasive neuromodulation and drug-delivery,” Juan-Pablo Mas, companion at Motion Potential Enterprise Capital, stated in an announcement. “APVC is proud to help the staff as they unwaveringly serve the healthcare professionals and sufferers whom this expertise can profit most.”
One other $40 million increase was introduced yesterday by decentralized medical trial startup Science 37. The oversubscribed spherical was dominated by present buyers: Lux Capital, Redmile Group and PPD, Inc. led the increase, whereas Novartis, Amgen, Sanofi Ventures, GV and Glynn Capital additionally participated. New backers LifeSci Ventures and Mubadala Ventures took half as nicely.
Seeing momentum from trial sponsor prospects all for digital recruitment instruments and BYOD help for contributors, the corporate stated these new funds will assist help development of its platform and its worldwide enterprise.
“The Science 37 mission to democratize medical analysis by bringing trials on to the sufferers is just not solely the fitting factor to do, however it additionally has had a transparent, measurable influence on sponsors’ skill to entry a extra numerous affected person inhabitants, speed up analysis, and produce new medicines to the market quicker,” David Coman, CEO of Science 37, stated in an announcement. “We’re thrilled to have an extremely sturdy, dedicated community of buyers and plan to proceed extending our management within the decentralized medical trial market.”
Thread, which additionally focuses on decentralized medical analysis expertise, revealed final week that it had raised strategic capital commitments of as much as $50 million from buyers Water Road Healthcare Companions and JLL Companions.
The Durham, North Carolina firm outlined a laundry checklist of objectives for the brand new funds, which included enlargement to greater than 40 international locations, growth and implementation of COVID-19 medical trial risk-mitigation instruments, the introduction of options for its platform, and the availability of worldwide and multilingual buyer help.
“Thread leads the business with its data and expertise in decentralized trials. This latest funding marks the subsequent section in our long-term strategic plan,” Dr. Mark A. Goldberg, govt chairman of Thread, stated in an announcement. “Working along with Water Road and JLL Companions, we’re deeply dedicated to preserving Thread on the forefront of offering purchasers with revolutionary, high-quality decentralized options they’ll depend on to soundly carry new therapies to market quicker.”
Bridge Connector, a vendor-agnostic healthcare interoperability startup, has closed a $25.5 million Collection B financing spherical. Led by Axioma Ventures and joined by the entire firm’s prior backers, this increase now brings Bridge to a lifetime funding complete of greater than $45 million.
Highlighting its greater than 1,000% year-over-year development in 2019 and its latest collaborations with Epic, Allscripts and Salesforce, the startup stated that it will be utilizing the funds to help its rising market share and its new Locations “integration-platform-as-a-service.”
“The corporate’s development within the two years since has validated our perception within the expertise and brightened the outlook for an interoperable well being care system,” Howard Jenkins, cofounding companion of Axioma Ventures, stated in an announcement. “With the corporate on monitor for 800% to 1,000% development in 2020, we’re wanting to see how our continued funding will assist Bridge Connector influence the business and create a well being care system that works higher for sufferers.”
Klara, a digital affected person messaging and engagement platform maker, has raised $15 million in a spherical co-led by Google’s Gradient Ventures and First Cressey Ventures. FirstMark Capital, Lerer Hippeau, Undertaking A and Stage 2 Capital additionally took half.
The corporate stated that these funds might be used for brand spanking new hires and enhancements to its choices. This contains further capabilities and better AI-based automation for affected person consumption and funds.
Trellus Well being, maker of a linked care platform for remedy of persistent illnesses reminiscent of inflammatory bowel illness, has introduced in $5 million in seed funding. Mount Sinai Well being System and EKF Diagnostics led the funding.
The corporate didn’t specify a right away aim for its new funds, however paired the funding announcement with information of an unique multiyear commercialization contract between the startup and Mount Sinai Well being System.
“We’re remodeling the way in which persistent situations are handled by creating a resilience-driven linked care platform that integrates precision medication with psychosocial care,” Monique Fayad, CEO of Trellus Well being, stated in an announcement.
“The normal journey of medical take care of individuals residing with persistent situations sometimes ends in repeated pricey, unplanned emergency room visits and hospitalizations, excessive charges of labor absenteeism and misplaced productiveness, in addition to persistent incapacity and behavioral well being points. We’re working to vary this by specializing in constructing sufferers’ resilience whereas integrating all companions in care, together with employers, insurance policy, well being techniques, Trellus-certified GI suppliers, nurses, psychologists, and dieticians who can make the most of Trellus Well being’s proprietary platform to successfully monitor and talk with sufferers and their caregivers in actual time.”